Forecast

Buy	2
Hold	3
Sell	0

News Go to news feed

Sandoz launches test market for semaglutide generics in Canada and Brazil

Sandoz plans test launches of a generic semaglutide injection in Canada and Brazil later this year to observe market reactions, price levels and patient segments. CEO Richard Saynor emphasizes great uncertainty about the market size after semaglutide patents expire and notes that a possible launch is not yet included in the 2026 forecast. Analyst estimates see rising sales of generic semaglutide in coming years, but the overall impact on Europe and the US remains unclear as exclusive rights still exist there. » More on finanzen.net
Sandoz launches Denosumab biosimilars Wyost and Jubbonti in Europe

Sandoz has launched the biosimilar copies Wyost and Jubbonti in Europe. The products target the market for denosumab patients and expand the generics and biosimilars specialist’s portfolio. » More on finanzen.net
Sandoz share: one-year gain of 36.1 percent

Had one invested 1,000 CHF in Sandoz a year ago, one would now hold 29.002 shares worth 1,361.37 CHF, corresponding to a price rise of 36.14 percent from the closing price of 34.48 CHF to 46.94 CHF (16 September 2025). The Sandoz share debuted on 4 October 2023 with an initial price of 24.00 CHF. Stock splits and dividends are not included in the calculation. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2024, Sandoz (ADR) has already paid 0,46€ in dividends. The last payout was in June 2024.

Financials

In the last quarter, Sandoz (ADR) had revenue of 5.06b€ and net profit of 95.71m€

(EUR)	Jun 2026	YoY
Revenue	+5.06b	-
Gross profit	+2.36b	-
Net profit	+95.71m	-
EBITDA	+982.60m	-

Fundamentals

Metric	Value
Market capitalization	+32.61b€
Number of shares	432.69m
52-week high/low	+80,82€ - +47,57€
Dividends	No
Beta	0,49
P/E ratio	+58,09
PEG ratio	+0,31
P/B ratio	+4,23
P/S ratio	+3,29

Company profile

Die Sandoz Group AG entwickelt, produziert und vertreibt weltweit generische Arzneimittel und Biosimilars. Sie entwickelt, produziert und vermarktet fertige Darreichungsformen von Arzneimitteln mit kleinen Molekülen für Dritte. Darüber hinaus bietet das Unternehmen Produkte auf Protein- oder anderer Biotechnologiebasis, einschließlich Biosimilars, sowie biotechnologische Produktionsdienstleistungen und Antiinfektiva, wie pharmazeutische Wirkstoffe und Zwischenprodukte, vor allem Antibiotika, an. Das Unternehmen wurde 1886 gegründet und hat seinen Hauptsitz in Rotkreuz, Schweiz.

Name	Sandoz (ADR)
CEO	Richard Saynor
Headquarters	Basel, zg Switzerland
Website	sandoz.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	10/04/2023
Employees	23.000